Growth Factors in Elderly Patients with Acute Myeloid Leukemia

[1]  J. Bennett,et al.  A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). , 1995, Blood.

[2]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[3]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[4]  R. Mayer,et al.  The approach to the elderly patient with acute myeloid leukemia. , 1993, Hematology/oncology clinics of North America.

[5]  M. Lewis,et al.  Mitozantrone and cytosine arabinoside as first‐line therapy in elderly patients with acute myeloid leukaemia , 1991, British journal of haematology.

[6]  W. Hiddemann,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. , 1991, Blood.

[7]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[8]  H. Tilly,et al.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Beuscart,et al.  Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.

[10]  B. Löwenberg,et al.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Willemze,et al.  Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. , 1989, Blood.

[12]  W. Hiddemann,et al.  Human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) treatment of patients with acute leukemias in aplasia and at high risk of early death. , 1988, Behring Institute Mitteilungen.

[13]  B. Coiffier,et al.  Treatment of acute myeloid leukemia in elderly patients. A retrospective study , 1988, Cancer.

[14]  Groupe Français de Cytogénétique Hématologique.  French registry of acute leukemia and myelodysplastic syndromes. Age distribution and hemogram analysis of the 4496 cases recorded during 1982–1983 and classified according to FAB criteria , 1987, Cancer.

[15]  J. Adamson,et al.  Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. , 1987, The New England journal of medicine.

[16]  H. Preisler,et al.  Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. , 1987, Blood.

[17]  R. Gray,et al.  PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.

[18]  F. Herrmann,et al.  Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. , 1986, Blood.

[19]  C. Begg,et al.  Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Estey,et al.  Causes of initial remission induction failure in acute myelogenous leukemia. , 1982, Blood.

[21]  J. Rowley,et al.  A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. , 1982, Blood.

[22]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[23]  T. Lister,et al.  Acute myeloid leukemia in elderly adults , 1990, Hematological oncology.

[24]  Edward J. Lee,et al.  Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.

[25]  H. Brincker.  Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. , 1985, Cancer treatment reports.